tbuckley/cabot-search huggingface dataset:
RANDOMIZED COMPARISON BETWEEN LOW (IOXIGLATO)AND ISO (IODIXANOL) OSMOLARITY IODINE CONTRAST FOR PREVENTION OF CONTRAT-INDUCED NEPHROPATY AMONG HIGH-RISK PATIENTS SUBMITTED TO PERCUTANEOUS CORONARY DIAGNOSTIC OR THERAPEUTIC PROCEDURES (THE IDPC TRIAL)
Authors: Jose de Ribamar Costa, Rafaela Penalva, Barbara Valente, Luiz Fernando Tanajura, Marinella Centemero, Alexandre Abizaid, Fausto Feres, Amanda G M R Souza, Joao Italo França
Journal: Journal of the American College of Cardiology (2020)
Metal-catechol-(amine) networks for surface synergistic catalytic modiﬁcation: Therapeutic gas generation and biomolecule grafting
Authors: Peng Gao, Hua Qiu, Kaiqin Xiong, Xiangyang Li, Qiufen Tu, Huaiyu Wang, Nan Lyu, Xiao Chen, Nan Huang, Zhilu Yang
Journal: Biomaterials (2020)
Oxygen Tension and the VHL-Hif1α Pathway Determine Onset of Neuronal Polarization and Cerebellar Germinal Zone Exit
Authors: Jan A. Kullmann, Niraj Trivedi, Danielle Howell, Christophe Laumonnerie, Vien Nguyen, Shalini S. Banerjee, Daniel R. Stabley, Abbas Shirinifard, David H. Rowitch, David J. Solecki
Journal: Neuron (2020)
CHARACTERISTICS OF CARDIAC AMYLOIDOSIS WITH ASYMMETRIC SEPTAL HYPERTROPY
Authors: Yasuhisa Nakao, Makoto Saito, Hiroe Morioka, Yuki Yokomoto, Akiyoshi Ogimoto, Katsuji Inoue, Shuntaro Ikeda, Osamu Yamaguchi
Journal: Journal of the American College of Cardiology (2020)
TRENDS AND PREDICTORS OF INPATIENT MORTALITY AMONG PATIENTS WITH MOOD DISORDERS UNDERGOING PCI
Authors: Anas A. Alharbi, Muhammad Khan, Bilal Munir, Muhammad Khan, Pratik Agrawal, Mohammed Osman, Kinjan Patel, Samian Sulaiman, Sudarshan Balla
Journal: Journal of the American College of Cardiology (2020)
Evolution of FLT3 Internal Tandem Duplication at the Diagnosis, Relapse, Remission or Induction Failure during the Treatment in Acute Myeloblastic Leukemia.
Authors: Soo-Mee Bang, Jeong Yeal Ahn, Jiyoon Park, Se Hoon Park, Eun Mi Nam, Eun Kyung Cho, Dong Bok Shin, Jae-Hoon Lee, Soo Jin Yoo, In Sang Jeon, Yeo-Kyeoung Kim, Hyeoung Joon Kim, Hee-Nam Kim, Il-Kwon Lee, Hyoung Jin Kang, Hee Young Shin, Hyo Seop Ahn
Journal: Blood (2006)
T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer
Authors: Aleksandar Z. Obradovic, Matthew C. Dallos, Marianna L. Zahurak, Alan W. Partin, Edward M. Schaeffer, Ashley E. Ross, Mohamad E. Allaf, Thomas R. Nirschl, David Liu, Carolyn G. Chapman, Tanya O'Neal, Haiyi Cao, Jennifer N. Durham, Gunes Guner, Javier A. Baena-Del Valle, Onur Ertunc, Angelo M. De Marzo, Emmanuel S. Antonarakis, Charles G. Drake
Journal: Clinical Cancer Research (2020)

Previous studies suggest that androgen deprivation therapy (ADT) promotes antitumor immunity in prostate cancer. Whether a vaccine-based approach can augment this effect remains unknown.We conducted a neoadjuvant, randomized study to quantify the immunologic effects of a GM-CSF-secreting allogeneic cellular vaccine in combination with low-dose cyclophosphamide (Cy/GVAX) followed by degarelix versus degarelix alone in patients with high-risk localized prostate adenocarcinoma who were planned for radical prostatectomy.Both Cy/GVAX plus degarelix and degarelix alone led to significant increases in intratumoral CD8+ T-cell infiltration and PD-L1 expression as compared with a cohort of untreated, matched controls. However, the CD8+ T-cell infiltrate was accompanied by a proportional increase in regulatory T cells (Treg), suggesting that adaptive Treg resistance may dampen the immunogenicity of ADT. Although Cy/GVAX followed by degarelix was associated with a modest improvement in time-to-PSA progression and time-to-next treatment, as well as an increase in PD-L1, there was no difference in the CD8+ T-cell infiltrate as compared with degarelix alone. Gene expression profiling demonstrated that CHIT1, a macrophage marker, was differentially upregulated with Cy/GVAX plus degarelix compared with degarelix alone.Our results highlight that ADT with or without Cy/GVAX induces a complex immune response within the prostate tumor microenvironment. These data have important implications for combining ADT with immunotherapy. In particular, our finding that ADT increases both CD8+ T cells and Tregs supports the development of regimens combining ADT with Treg-depleting agents in the treatment of prostate cancer.
VERY LONG-TERM SURVIVAL OF PAEDIATRIC LOW GRADE GLIOMA PATIENTS; POSSIBLE ROLE OF BRAF-KIAA1549 FUSION
Authors: Nataliya Zhukova, Jason Pole, Matthew Mistry, Iris Fried, Ute Bartels, Annie Huang, Normand Lapperiere, Peter Dirks, Katrin Scheinemann, Jason An, Noa Alon, Paul Nathan, Mark Greenberg, Eric Bouffet, David Malkin, Cynthia Hawkins, Uri Tabori
Journal: Neuro-Oncology (2013)
Continuous Nursing Support During Labor—Reply
Authors: Ellen Hodnett
Journal: JAMA (2003)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ASSESSMENT OF THE LEFT VENTRICULAR DIASTOLIC FUNCTION AFTER PERCUTANEOUS ATRIAL SEPTAL DEFECT CLOSURE IN CHRONIC PHASE
Authors: Kenji Makino, Go Hashimoto, Suzuki Makoto, Hiromasa Hayama, Takenori Otsuka, Nobutaka Ikeda, Raisuke Iijima, Hidehiko Hara, Masao Moroi, Masato Nakamura
Journal: Journal of the American College of Cardiology (2020)
Achieving patient health outcomes via CME: A case-study in educating oncologists in the treatment of non-small cell lung cancer.
Authors: Tom Bregartner
Journal: Journal of Clinical Oncology (2013)

e19104 Background: The Validation Model is an educational series built on the concept of strengthening education by incorporating the patient perspective. After conducting two iterations of the Validation Model to educate oncologists in the treatment of NSCLC, Quintiles Medical Education was able to demonstrate that CME can lead to improved patient health outcomes by changing physician behaviors in practice. Educational measurement tools, including chart audits, revealed an increase in tumor histology and EGFR mutation testing. Histologic and molecular marker testing leads to optimization of treatment based on tumor pathology and genotype, respectively, as per NCCN guidelines. Personalization of treatment according to guidelines results in improved health outcomes. Methods: The Validation Model consisted of 6 educational activities for which efficacy was measured by conducting pre- and post-tests of knowledge and clinical competence among participants. Participants were then asked to complete a follow-up survey which was designed to determine if specific practices had been implemented since participation. The self-self reported behavioral data was validated by the distribution of patient surveys, designed to measure patient satisfaction and expectation with care, and chart audits, designed to determine the actual practice habits of the participating practitioners. Results: More than 500 participants have completed all 6 of the educational activities. The activities have demonstrated improved knowledge and competence in the educational setting and changes to clinical practice and, as a result, patient health outcomes. Conclusions: CME can be used as an effective tool to improve patient health outcomes in the treatment of NSCLC.
Integrating Responses to the Opioid Use Disorder and Infectious Disease Epidemics
Authors: Sandra A. Springer, Andrew P. Merluzzi, Carlos del Rio
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Use of the eLogbook in surgical training in the United Kingdom: A nationwide survey and consensus recommendations from the Association of Surgeons in Training
Authors: A.J. Beamish, M.J. Johnston, R.L. Harries, H. Mohan, J.E.F. Fitzgerald, G. Humm, M. Rabie, D.M. Nally, V.J. Gokani, Oroog Ali, Joshua Burke, Joshua M. Clements, Vanessa Cubas, Christina Fleming, Lolade Giwa, James Glasbey, Vimal J. Gokani, Gianluca Gonzi, Rhiannon Harries, Katie Hughes, Elizabeth G. Kane, Kirsty MacLeod, Miriam Manook, Helen Mohan, Deirdre Nally, Philip H. Pucher, Kapil Sahnan, Fenella Shelton, Nisaharan Srikandarajah, Matthew Stovell, Anthony Thaventhiran, Nathan R. Walker, Alex Wilkins
Journal: International Journal of Surgery (2020)
Familial Coaggregation of Asthma and Type 1 Diabetes in Children
Authors: Awad I. Smew, Cecilia Lundholm, Lars Sävendahl, Paul Lichtenstein, Catarina Almqvist
Journal: JAMA Network Open (2020)

<h3>Importance</h3> The association between atopic and autoimmune disease, particularly asthma and type 1 diabetes, has been debated. Further understanding of the underlying factors associated with the comorbidity in children is warranted. <h3>Objectives</h3> To assess the bidirectional association between asthma and type 1 diabetes and examine the possibility of a shared risk for the diseases by studying their pattern of familial coaggregation. <h3>Design, Setting, and Participants</h3> A birth cohort study of children born from January 1, 2001, and followed up until December 31, 2015, was performed. Population data were obtained from multiple national Swedish registers. A total of 1 347 901 singleton children, live-born in Sweden between January 1, 2001, and December 31, 2013, were identified, and children with incomplete data were excluded. The remaining 1 284 748 children were linked to their biological full siblings, maternal and paternal half-siblings, cousins, and half-cousins. Data analysis was conducted from April 1, 2019, to January 17, 2020. <h3>Main Outcomes and Measures</h3> Cases of asthma and type 1 diabetes were defined using a combination of diagnoses and medication prescriptions found in the registers. <h3>Results</h3> In the cohort of 1 284 748 children, 660 738 children (51.4%) were boys; 121 809 children (9.5%) had asthma, 3812 children (0.3%) had type 1 diabetes, and 494 children had both asthma and type 1 diabetes, representing 0.4% of all asthma or 13% of all type 1 diabetes. Mean (SD) age at diagnosis was 3.0 (2.8) years for children with asthma, and 5.9 (3.3) years for those with type 1 diabetes. Asthma and type 1 diabetes were associated within individuals (odds ratio, 1.15; 95% CI, 1.05-1.27). Children with asthma had an increased risk of subsequent type 1 diabetes (hazard ratio, 1.16; 95% CI, 1.06-1.27); however, subsequent asthma risk did not differ substantially among children with type 1 diabetes (hazard ratio, 0.92; 95% CI, 0.75-1.12). Siblings of individuals with asthma were at an increased risk of type 1 diabetes (odds ratio, 1.27; 95% CI, 1.13-1.42) and vice versa. The results remained positive after controlling for the direct association of one disease with the other. <h3>Conclusions and Relevance</h3> This study appears to provide evidence for co-occurrence, importance of sequential appearance, and coaggregation of asthma and type 1 diabetes in children and their siblings. The findings may suggest shared familial factors contributing to the associations. Knowledge of the nature of the association could be of importance in future clinical practice.
TRENDS AND PREDICTORS OF NOAC VERSUS WARFARIN USE FOR STROKE PREVENTION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
Authors: Kenneth B. Brownell, Ahmet Sezer, Sandeep Jain, Floyd Thoma, Krishna Kancharla, Aditya Bhonsale, Samir Saba, Suresh Mulukutla
Journal: Journal of the American College of Cardiology (2020)
PREDICTORS OF CONDUCTION RECOVERY IN PATIENTS WITH HIGH-DEGREE ATRIOVENTRICULAR BLOCK AFTER SELF-EXPANDABLE TRANSCATHETER AORTIC VALVE REPLACEMENT
Authors: Abdur Rahman Ahmad, Ana Cristina Perez Moreno, Khawaja Afzal Ammar, Arshad Jahangir, Tanvir Bajwa, Jodi Zilinski
Journal: Journal of the American College of Cardiology (2020)
LEFT VENTRICULAR ASSIST DEVICE OUTFLOW TRACK TWIST MASQUERADING AS RV FAILURE
Authors: Ioannis Mastoris, Abdulelah Nuqali, Siva Sagar Taduru, Mohamed El Khashab, Mallory Buck, Zubair Shah, Nicholas Haglund, Andrew Sauer, Travis Abicht
Journal: Journal of the American College of Cardiology (2020)
A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS EVALUATING RENAL DENERVATION FOR UNCONTROLLED AND RESISTANT HYPERTENSION
Authors: Adrian V. Hernandez, Jonathan Silverwatch, Mi T. Phan, Hinali Amin, Yuani M. Roman, Joshuan Barboza Meca, Vinay Pasupuleti, Maciej Banach
Journal: Journal of the American College of Cardiology (2020)
Exercise and Intermittent Claudication
Authors: JAMES S. SKINNER, D. EUGENE STRANDNESS
Journal: Circulation (1967)

Five men with arteriosclerosis obliterans (ASO) underwent a 3 to 8-month physical training program. The systolic pressure at the ankle (AP) before and after exercise, maximal walking time (MWT), and time of onset of claudication pain (CPT) were recorded on 4 different days. After training, these measurements were repeated on 3 different days. In addition, each subject was retested at his initial MWT. There were significant increases in resting AP levels of three subjects, in CPT and MWT of all five subjects and in the postexercise AP levels of all five subjects. Pain diminished or disappeared for varying periods of time while four of the subjects were walking. These data signify that there was a significant increase in collateral circulation at rest, during or after exercise, or both, improving the blood supply to the obstructed leg.
Outcome of patients with non-metastatic versus metastatic hormone refractory prostate cancer (HRPC) treated with second-line hormonal therapy consisting of ketoconazole (keto) plus granulocyte macrophage colony stimulating factor (GM-CSF)
Authors: C. J. Ryan, J. Rosenberg, A. Lin, L. Ruttner, V. Weinberg, E. Small
Journal: Journal of Clinical Oncology (2006)

4626 Background: Second line hormonal manipulations are frequently used in pts with HRPC. It is unknown if these manipulations are more effective in patients without clinical metastases. The efficacy of a second-line hormonal manipulation (keto plus GM-CSF) was prospectively evaluated in a cohort of HRPC patients with and without metastases. Methods: Eligible pts had progressive HRPC by consensus criteria, no prior immunotherapy, chemotherapy or keto. Pts received keto 400 mg po tid and hydrocortisone 20 mg po qAM and 10 mg po qPM. GM-CSF 250 mcg/m 2 was administered SQ on days 15–28 of each 28-day cycle. Results: Forty-two of 48 planned pts have been enrolled, 30 with clinical metastases, 12 with PSA-only disease and are evaluable for PSA response, using consensus criteria. The median age is 68 years (range: 53–84), and median PSA 23.1 ng/mL (range: 5.4–306.5). The median treatment duration is 5.1 months (range: 0.3–22+). Overall, 30 of 43 patients (69%) have experienced a ≥ 50% reduction in PSA. The PSA response proportion in the non-metastatic patients is 8/12 (66%) while the response proportion in those with metastases is 16/30 (53%, chi squared p = 0.41). Twenty-three patients have discontinued therapy after a median of three cycles. Progressive disease has occurred in 17 patients, 3 of 12 patients with non-metastatic disease and in 14 of 30 patients with metastatic disease (25% vs. 47%, chi squared p=0.20). Six patients have discontinued due to toxicity or patient choice. The primary endpoint of the study, overall time to progression, has not been reached at a median follow up of 7 months. Conclusions: There was no significant difference in response proportion and progressive disease rate in HRPC patients with and without metastatic disease treated with keto/GM-CSF. While these data require prospective confirmation in a larger group of patients, they suggest that secondary hormonal manipulations are warranted in either patient group. No significant financial relationships to disclose.
CONSISTENT BENEFIT OF DAPAGLIFLOZIN ACCORDING TO BACKGROUND THERAPY IN PATIENTS WITH HFREF: AN ANALYSIS OF THE DAPA-HF TRIAL
Authors: Kieran Docherty, Alice Jackson, Silvio E. Inzucchi, Pardeep Jhund, Lars Kober, Mikhail Kosiborod, Anna Maria Langkilde, Felipe Martinez, Olof Bengtsson, Piotr Ponikowski, Marc Sabatine, Mikaela Sjoestrand, Scott D. Solomon, Akshay S. Desai, Mirta Diez, Jonathan Howlett, Charlotta E.A. Ljungman, Eileen O'Meara, Mark Petrie, Morten Schou, Vinh Pham, John McMurray
Journal: Journal of the American College of Cardiology (2020)
Longitudinal evaluation of peripheral nerve sheath tumors in neurofibromatosis type 1: growth analysis of plexiform neurofibromas and distinct nodular lesions
Authors: Srivandana Akshintala, Andrea Baldwin, David J Liewehr, Anne Goodwin, Jaishri O Blakeley, Andrea M Gross, Seth M Steinberg, Eva Dombi, Brigitte C Widemann
Journal: Neuro-Oncology (2020)

Abstract Background Understanding the natural history of non-malignant peripheral nerve sheath tumors (PNSTs) in neurofibromatosis type 1 (NF1) is critical to optimal clinical care and the development of meaningful clinical trials. Methods We longitudinally analyzed growth of plexiform neurofibromas (PNs) and of PNSTs with distinct nodular appearance (distinct nodular lesions [DNLs]) using volumetric MRI analysis in patients enrolled on a natural history study (NCT00924196). Results DNLs were observed in 58/122 (45.6%) patients (median 2 DNLs/patient). In DNLs that developed during follow-up, median age of development was 17 years. A moderate negative correlation was observed between the estimated PN growth rate and patients’ age at initial MRI (Spearman’s r [95% CI]: −0.60 [−0.73, −0.43], n = 70), whereas only a weak correlation was observed for DNLs (Spearman’s r [95% CI]: −0.25 [−0.47, 0.004]; n = 61). We observed a moderate negative correlation between tumor growth rate and baseline tumor volume for PNs and DNLs (Spearman’s r [95% CI]: −0.52 [−0.67, −0.32] and −0.61 [−0.75, −0.42], respectively). Spontaneous tumor volume reduction was observed in 10 PNs and 7 DNLs (median decrease per year, 3.6% and 7.3%, respectively). Conclusion We corroborate previously described findings that most rapidly growing PNs are observed in young children. DNLs tend to develop later in life and their growth is minimally age related. Distinct growth characteristics of PNs and DNLs suggest that these lesions have a different biology and may require different clinical management and clinical trial design. In a subset of PNs and DNLs, slow spontaneous regression in tumor volume was seen.
Recurrent/progressive oligodendroglial tumors: A phase II study with temozolomide as first line chemotherapy
Authors: R. Soffietti, R. Rudà, D. Guarneri, E. Laguzzi, E. Trevisan
Journal: Journal of Clinical Oncology (2006)

1561 Background: There are few data regarding the efficacy of first line temozolomide in recurrent oligodendroglial tumors, and responses range from 17% to 54%. The objective of this phase II study was to investigate the efficacy and toxicity of temozolomide in the “standard schedule” in patients with oligodendroglial tumors at first relapse after surgery alone or surgery plus radiotherapy. Methods: The main inclusion criteria were as follows: age ≥ 18 yrs, Karnofsky ≥ 70; diagnosis of oligodendroglioma or oligoastrocytoma (grade II or III) according to WHO. Temozolomide was administered in the standard regimen up to 24 cycles in responding or stable patients or to unacceptable toxicity. Primary endpoint was response basing on Macdonald’s criteria, whereas secondary end-points were time to tumor progression and progression-free survival at 6 and 12 months. Results: Fifty patients are evaluable, with a median age of 50 (range 19–72). A median of 12 cycles (range 1–24) were administered. Responses were as follows: CR 8/50 (16%); PR 13/50 (26%); mR (minor response, a tumor volume reduction of 20–40%) 7/50 (14%); SD 18/50 (36%); PD 4/50 (8%). The overall response rate (CR+PR+mR) was 56%. The maximum tumor response was observed after 3 cycles in 9/28, 6 cycles in 10/28, 9 cycles in 6/28, 12 cycles in 1/28, 15 cycles in 2/28. Fourteen of 28 responding (CR+PR+mR) patients (50%) and 8 of stable patients (44%) displayed a reduction of seizures. Eighteen of 35 (51%) oligodendrogliomas responded, including 7 patients with CR (5 grade III tumors and 2 grade II), compared to 10/15 (67%) oligoastrocytomas. Twenty of 35 enhancing tumors responded (57%) compared to 8/15 non-enhancing tumors (53%) and 57% of grade III responded compared to 55% of grade II. Median TTP was 17 months (range 2–37), with a PFS at 6 months of 40% and at 12 months of 29%. Grade III-IV myelotoxicity accounted for 22%. Conclusions: Temozolomide shows activity as first line treatment in oligodendroglial tumors at first relapse. A long term treatment with temozolomide is well tolerated. No significant financial relationships to disclose.
PROGNOSTIC VALUE OF LEFT VENTRICULAR MASS MEASURED ON POSITRON EMISSION TOMOGRAPHY IN PATIENTS WITH AND WITHOUT CORONARY ARTERY DISEASE
Authors: Ahmed Hamad Aljizeeri, Mousa Alali Alfaris, Dalia Ahmed, Jabir Farea, Awakelkarim Elneama, Ihab Suliman, Mohsen Alharthi, Amjad M. Ahmed, Ahmed Alsaileek, Mouaz H. Al-Mallah
Journal: Journal of the American College of Cardiology (2020)